A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms REBUILD-2
- Sponsors Eli Lilly and Company
- 23 Mar 2023 Planned End Date changed from 8 Mar 2024 to 30 Jul 2025.
- 23 Mar 2023 Planned primary completion date changed from 12 Feb 2023 to 30 Jul 2025.
- 22 Dec 2020 Status changed from not yet recruiting to recruiting.